Relationship between serum RANKL and RANKL in bone - Wikidata - wikimedia - TriplyDB

Relationship between serum RANKL and RANKL in bone

Relationship between serum RANKL and RANKL in bone

http://www.wikidata.org/entity/Q28245828

about

Targeting RANKL in metastasis Novel biological markers of bone: from bone metabolism to bone physiology The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues.Changes of serum soluble receptor activator for nuclear factor-κB ligand after glucocorticoid therapy reflect regulation of its expression by osteoblasts Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor- κ B Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus.Osteocyte regulation of bone mineral: a little give and take.Effects of short-term dry immersion on bone remodeling markers, insulin and adipokines.Relaxin and insulin-like peptide 3 in the musculoskeletal system: from bench to bedside.The Utility of Biomarkers in Osteoporosis Management.Associations between OPG and RANKL polymorphisms, vertebral fractures, and abdominal aortic calcification in community-dwelling older subjects: the Sao Paulo Ageing & Health Study (SPAH).Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial.The role of serum osteoprotegerin and receptor-activator of nuclear factor-κB ligand in metabolic bone disease of women after obesity surgery.Circulating Levels of Soluble Receptor Activator of NF- κ B Ligand and Matrix Metalloproteinase 3 (and Their Antagonists) in Asian Indian Patients with Ankylosing Spondylitis.TNF-α has both stimulatory and inhibitory effects on mouse monocyte-derived osteoclastogenesis The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial.Effects of different orthodontic retention protocols on the periodontal health of mandibular incisors.The Assessment of Bone Regulatory Pathways, Bone Turnover, and Bone Mineral Density in Vegetarian and Omnivorous Children.Anodized 3D-printed titanium implants with dual micro- and nano-scale topography promote interaction with human osteoblasts and osteocyte-like cells.Aconitum pseudo-laeve var. erectum inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclastogenesis via the c-Fos/nuclear factor of activated T-cells, cytoplasmic 1 signaling pathway and prevents lipopolysaccharide-induced bon Circulating Levels of Bone and Inflammatory Markers in Gestational Diabetes Mellitus

P2860

Q26849690-6C62E046-EABA-404E-813F-324BA47BF79C Q28067712-03A9EA93-333F-499D-BD47-42A19D58A872 Q35838186-A9B49FE4-D724-45C9-9E65-4B596B137247 Q36293557-1A95B09F-3D90-476C-8A3C-37CBD243703C Q37322445-31A18DFB-5FFE-4844-8302-A0ED7EAA34A9 Q37981072-77174679-B5E4-44B6-83E7-9C13DA772141 Q38625798-94C034AF-644D-4C21-B437-36125CDF404E Q38802490-6F3CB6D9-AA5A-4908-85D7-535FD890DE4B Q38921875-CA566109-FAF5-41F9-8EFB-CEBE8664B93E Q39677675-5C00B498-5C51-423F-B6AD-EF1F6644C231 Q40154450-DDE5FE1B-6592-45A6-BAC8-2290057DE61C Q40464930-227C3A50-D510-4771-A660-1BE227AD7491 Q41884710-AA090790-FF3D-4905-B920-4CD0783F77EE Q42035093-C700AF12-BE44-4BD2-B0FC-DFF6766F0632 Q46125695-BADC6246-0A38-4197-A627-46AFD6D8035A Q47683007-9BB37B10-2281-4E8C-A051-68D0EB2FEE26 Q50133867-E8208C4F-B3CC-4435-AD59-E361DDEA880D Q51084648-7A47D6DA-CD53-40A3-9693-DD5A228396D0 Q53266240-C702FF23-883C-4841-82EE-484EBCC6F7BB Q58805499-14A3FDFE-CA64-4387-B497-E0A33D9D122B

P2860

Relationship between serum RANKL and RANKL in bone

http://www.wikidata.org/entity/Q28245828

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Relationship between serum RANKL and RANKL in bone

@ast

Relationship between serum RANKL and RANKL in bone

@en

Relationship between serum RANKL and RANKL in bone

@nl

type

label

Relationship between serum RANKL and RANKL in bone

@ast

Relationship between serum RANKL and RANKL in bone

@en

Relationship between serum RANKL and RANKL in bone

@nl

prefLabel

Relationship between serum RANKL and RANKL in bone

@ast

Relationship between serum RANKL and RANKL in bone

@en

Relationship between serum RANKL and RANKL in bone

@nl

P1433

Q28245828-2CDFDA67-BC7D-4368-A4A8-0452D18A21C8

P1476

Q28245828-C74B5A02-EEF6-4629-B4D7-8A04351BC6D8

P2093

Q28245828-EA9E0D49-7A7A-4117-9406-A774A344172D

P2860

Q28245828-02649967-7E9F-475E-96D0-FA572A910826

Q28245828-0356532C-886E-4DC4-A374-9DD7B54799F3

Q28245828-11545CE7-3F0E-4857-8566-A8DD8F997DEC

Q28245828-135DE1A6-8B2A-4247-BB30-81C552C6F33D

Q28245828-15D61772-EC1E-4E45-A9B3-74C004F13087

Q28245828-17321C1C-F13D-4218-B7E5-8B658DA716DC

Q28245828-1EE41551-8E15-42A0-848A-4F2FF7511E21

Q28245828-23D8CD4B-D99F-481D-915E-A3E7C0DE6C56

Q28245828-23F7E306-6036-484A-8770-C9577C102113

Q28245828-24D81DB4-1DA5-443E-90BC-E96A0BD7312C

P2888

Q28245828-D87761EA-8424-4CAC-A9A4-276C587D400D

P304

Q28245828-B8146BF6-2AE9-4E50-B1E4-D2F8A6BA1183

P31

Q28245828-E0039650-9FF1-47AE-968B-5343045EF226

P356

Q28245828-7AF55E26-8656-4E5C-A6E9-CF8EDB7847BF

P407

Q28245828-FA3B14BF-404C-47CB-8879-6D48F27B91A0

P433

Q28245828-9851ED07-B5EA-48E6-902C-B8CEF5658737

P478

Q28245828-6BB152AF-483F-4C78-BE07-ACA5A3DEA629

P50

Q28245828-33ADA1E5-07D6-4EED-80EC-2C1F6FDA497A

P577

Q28245828-AFD4E010-FA0F-4035-9A59-DCF93532F1B7

P698

Q28245828-55B456FD-A215-4DEF-ADA0-8D9CE7346909

P356

S00198-011-1740-9

P1433

Osteoporosis International

P1476

Relationship between serum RANKL and RANKL in bone

@en

P2093

D M Findlay

http://www.w3.org/2001/XMLSchema#string

P2860

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.

Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

P2888

s00198-011-1740-9

P304

2597-2602

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00198-011-1740-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Gerald J Atkins

P577

2011-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21850548

http://www.w3.org/2001/XMLSchema#string